Could next-generation sequencing improve breast cancer patient outcomes in Germany?

Written by Rachel Jenkins, Future Science Group

NGS

Breast cancer patients in Germany will now have access to state-of-the-art genomic profiling in their own country. Recently announced by Agendia Inc (CA, USA), the availability of local testing using their CE-marked MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping tests will be provided by PathoNext lab (Leipzig, Germany). MammaPrint testing analyzes the 70 most common genes associated with breast cancer recurrence and provides a low or high risk of cancer recurrence result. Blueprint testing analyzes 80 genes that classify a patient’s breast cancer into functional molecular subtypes. Prior to this announcement, tests had been performed via microarray at Agendia’s...

To view this content, please register now for access

It's completely free